Richard Brodsky is a highly skilled and experienced leader in the biopharmaceutical industry, with an impressive track record of more than 25 years working at top-tier companies like Pfizer, Alexion, and Naveos Biopharma Consulting. His most recent corporate role in Global Marketing Leadership saw him successfully launch Soliris for Myasthenia Gravis, an achievement that marked the first product approved for MG in 60 years. 

Rich's background in science and business is both varied and extensive, and he has worked with numerous disease and technology areas. His passion lies in specialty and rare diseases, gene therapies, neuroscience, and immunology. He is well-versed in the global healthcare environment, customers' needs, and key market trends, with unparalleled knowledge of the product lifecycle spectrum, from clinical development to launch and in-line marketing.

Rich has led many high-performing cross-functional teams in various efforts, including therapeutic strategy development, commercial development, global product launch, portfolio management, and licensing/acquisition evaluations. As the founder of Naveos Biopharma Consulting, he leverages his experience to help clients with critical activities such as new product launch planning, long-range forecasting, market development, global positioning, KOL development, lifecycle planning, and business development. Rich also serves as an ongoing interim commercial leader for earlier-stage biotechs and leads fixed projects, focusing on bridging business strategy and scientific innovation.

Rich obtained his BS in Mechanical Engineering and MBA from the University of Michigan.